Evidence map›Paper›PMID 34830872›Full record

ArticleCancers2021

Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients.

Fien H R De Winter, An Hotterbeekx, Manon T Huizing, Angelina Konnova, Erik Fransen, Bart's Jongers, Ravi Kumar Jairam, Vincent Van Averbeke, Pieter Moons, Ella Roelant and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. High Risk of Heart Tumors after COVID-19.Life (Basel, Switzerland) · 2023
    Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Fien H R De WinterMolecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0003-3803-7813
An HotterbeekxMolecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0003-3356-4032
Manon T HuizingMultidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.ORCID 0000-0001-5331-9486
Angelina KonnovaMolecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0001-9353-8026
Erik FransenStatUa, Center for Statistics, University of Antwerp, 2000 Antwerp, Belgium.
Bart's JongersMolecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Ravi Kumar JairamMolecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Vincent Van AverbekeMolecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Pieter MoonsBiobank Antwerp, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.ORCID 0000-0002-9830-0444
Ella RoelantStatUa, Center for Statistics, University of Antwerp, 2000 Antwerp, Belgium.
Debbie Le BlonCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Wim Vanden BerghePPES Lab Protein Chemistry, Proteomics & Epigenetic Signaling, IPPON, Department Biomedical Sciences, University Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0003-0161-7355
Annelies JanssensMultidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.
Willem LybaertDepartment of Medical Oncology, AZ Nikolaas, Moerlandstraat 1, 9100 Sint-Niklaas, Belgium.
Lieselot CroesCenter for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Christof VulstekeClinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp, Drie Eikenstraat 655, 2650 Edegem, Belgium.
Surbhi Malhotra-KumarLaboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Herman GoossensLaboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Zwi BernemanMultidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.
Marc PeetersMultidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.
Peter A van DamMultidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium.ORCID 0000-0002-9184-7703
Samir Kumar-SinghMolecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0001-9466-6732
University of Antwerp · BEAntwerp University Hospital · BE

Funding

Horizon 2020 OrchestraInnovative Medicines Initiative 115523 and 115737Kom Op Tegen Kanker 000100470Research Foundation - Flanders FWO-SB151525 and FWO-1S93418NUniversity of Antwerp 42839University of Antwerp s30729UZA Foundation grant 2020
6 · The paper itself

Abstract

Cytokines, chemokines, and (angiogenic) growth factors (CCGs) have been shown to play an intricate role in the progression of both solid and haematological malignancies. Recent studies have shown that SARS-CoV-2 infection leads to a worse outcome in cancer patients, especially in haematological malignancy patients. Here, we investigated how SARS-CoV-2 infection impacts the already altered CCG levels in solid or haematological malignancies, specifically, whether there is a protective effect or rather a potentially higher risk for major COVID-19 complications in cancer patients due to elevated CCGs linked to cancer progression. Serially analysing immune responses with 55 CCGs in cancer patients under active treatment with or without SARS-CoV-2 infection, we first showed that cancer patients without SARS-CoV-2 infection (

Indexed as

anti-inflammatoryCOVID-19haematological cancersimmune responsepro-inflammatorysolid cancersTh1Th17Th2

Identifiers

PMID34830872
PMCPMC8616215
OpenAlexW3213247708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.